Opendata, web and dolomites

GI-BCT SIGNED

Disruptive imaging technology for accurate and painless breast cancer diagnosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GI-BCT project word cloud

Explore the words cloud of the GI-BCT project. It provides you a very rough idea of what is the project "GI-BCT" about.

solid    investment    healthcare    outcomes    saving    gratxray    640    5m    computed    contracts    first    routing    procedure    survival    sold    disease    women    service    size    patents    95    dense    therapeutic    cancer    roi    85b    provides    3d    later    compression    207    trials    agents    15    meur    team    21    employees    portfolio    resolution    environment    clinical    breasts    contrast    ready    natural    stage    patient    combines    gi    market    mortality    centers    limited    reduce    q1    scanned    formed    avoiding    worked    sales    68    amount    unnecessary    entering    painless    revenue    images    56    detection    hired    patients    net    tissue    discovered    poor    start    tomography    industry    die    prevalent    beur    scientific    performing    granted    interferometry    rate    positives    commercialization    demonstrated    mammography    precise    false    yielding    save    imaging    painful    disruptive    2021    lowering    profits    potentially    estimate    treatment    patent    efficient    bct    grating    produces    2d    form    programs    machinery    missed    59    countries    discrimination    breast    recalls    400    screening   

Project "GI-BCT" data sheet

The following table provides information about the project.

Coordinator
GRATXRAY AG 

Organization address
address: PARK INNOVAARE
city: VILLIGEN
postcode: 5234
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.gratxray.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GRATXRAY AG CH (VILLIGEN) coordinator 50˙000.00

Map

 Project objective

Breast cancer is the most prevalent form of cancer in women, as 1 in 9 women are affected and 1 in 30 will die from the disease. Early detection is essential to reduce the mortality, thus countries have established routing screening programs. The problem is that main screening procedure of mammography is painful for patients, produces high rate of false positives for women with dense breast tissue, provides limited contrast, low-resolution and poor tissue discrimination properties. False positives lead to performing unnecessary therapeutic procedures. Also cancer in dense breasts is missed out by mammography, lowering survival outcomes when discovered in later stage. GratXray is entering the 3,56 BEUR size breast imaging market with our disruptive grating interferometry-based breast computed tomography – GI-BCT technology. GI-BCT will provide painless, efficient and precise breast cancer imaging. The breast will be scanned in its natural state in 3D, without compression and contrast agents, yielding images with a much higher contrast and better resolution. Thus saving €1,85B in healthcare costs in Europe and US by avoiding recalls, €640 000 from machinery costs for breast centers and potentially save treatment costs in the amount of €95 000 per patient. We have worked for the past 15 years in GI-BCT research and have a solid patent portfolio of 8 granted patents. Currently, we have demonstrated our technology in operational environment, and we are ready to start first clinical trials in 2D with the goal to make first sales in Q1 2021. We have formed a team that combines strong scientific, industry and user know-how. We estimate that a further investment of €5M and 3 years is required to reach the commercialization stage. We estimate that in year 6 we have hired 50 employees, sold 59 systems per year, have 207 service contracts, revenue of 68 MEUR, net profits of 21 MEUR and reach ROI of 4 (400%).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GI-BCT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GI-BCT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More